ASND Ascendis Pharma A/S
USHealthcareAs of 2026-07-09 16:00
Why ASND matters now
Ascendis Pharma A/S (ASND) is a US stock in Healthcare. The latest InvestLog snapshot shows $275.43 with -0.63% on the session and $17.11B in market capitalization; recent performance reads 1-month -3.00% and YTD +8.25%.
The latest financial table shown here is Q1 2026, with revenue of $250.7M, net income of $639.7M, and EPS of $9.91. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.3%.
The latest indexable market news headline is "Why Crinetics Stock Soared 99% This Week" from 24/7 Wall Street.
Additional event context on this page matters because analyst consensus is Buy with a median target of $267.50; recent insider activity includes SMITH SCOTT THOMAS filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
25.41
P/S
14.41
EV/EBITDA
1036.76
DCF Value
$-5,101.33
FCF Yield
0.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.2%
Operating Margin
-0.8%
Net Margin
58.4%
ROE
-5641.9%
ROA
25.3%
ROIC
1.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $250.7M | $639.7M | $9.91 |
| Q4 2025 | $245.2M | $-33.2M | $-0.54 |
| FY 2025 | $691.7M | $-219.0M | $-3.62 |
| Q3 2025 | $213.6M | $-61.0M | $-1.00 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$287.50
Target (Median)
$267.50
Target Range
$250.00 - $345.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
DK
Exchange
—
Beta
0.39
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.